



Fax: 866-336-9530
Toll Free: 1-866-DEO-9530
E-mail: investorinfo@deobiosciences.com
www.deobiosciences.com

John F. Adamson, Jr.
President & CEO

January 21, 2022

Dear Investors and Followers:

New Advisory Board Member:

We explained in our offering page that we would add expertise to our operations and advisory board, as appropriate for that particular phase of development. Well, we're happy to announce the impending addition of an advisory board member. We've only reached a verbal agreement as of this moment but written acceptance of the terms of service and IP confidentiality are soon to come. Until then, I won't officially announce their name but I can say that they are a widely respected biochemist who chairs the Department of Molecular Pharmacology at an Ivy League university (not Cornell) and have a multi-decade history as both an NIH scientist and academic professor. We're excited to have access to their intellect and unique expertise and will share their name and more about their background, once we finalize the documents.

JP Morgan Healthcare Conference 2022

The JP Morgan Healthcare Conference is an annual event in San Francisco that is like a global convention for the pharmaceutical and biotech industries. It's an opportunity to learn about the upcoming companies and trends and network with major industry players and companies. This year it was conducted virtually on-line and I attended some noteworthy sessions about the direction of the industry.

I wanted to share one of them here because it helps inform you about the mind set and thinking of a major segment of the industry and how it could impact our future plans and opportunities. I'm sharing the following link to the interview of Jay Bradner, president of the Novartis Institutes for BioMedical Research. The article basically explains how Novartis is looking for innovative drug approaches and not simply "copycat" approaches of existing drugs and is urgently requesting small and early-stage biotechs to reach out to explore partnering and licensing opportunities. For example, Bradner stated:

"We absolutely have a real hungry appetite to do deals, whether they're early-stage partnerships or partnerships to bring later-stage assets to patients around the world through the intergalactic capabilities of our global pharmaceutical company," Bradner said. "I can assure you that the demand and appetite is there."

Of course, this isn't a guarantee that we will have any opportunity to partner with such a large company, but it is an example of the industry demand for new biotechnologies and eagerness to work with even small companies that can demonstrate the potential to make an impact. Here's the link:

<https://www.fiercebiotech.com/biotech/fierce-jpm-week-as-novartis-hunts-for-m-a-gems-among-me-too-companies-r-d-chief-urges>

Again, this validates one of our strategies to obtain compelling proof-of-concept data and selectively target partnerships with larger established companies with the resources to accelerate our development. I just wanted to share some recent developments in my week as we head into the last phase of our Netcapital campaign.

Thank you again for being a visionary and fearless ground-floor partner in our journey! More to come. Until next time, be well.

A handwritten signature in black ink, appearing to be 'John A.', written in a cursive style.

John A. & Team DeoBioSciences